<DOC>
	<DOC>NCT02378506</DOC>
	<brief_summary>Open-label immunogenicity, safety and efficacy study of etanercept manufactured using the high capacity process. Descriptive results will be provided however a formal hypothesis will not be tested in this trial.</brief_summary>
	<brief_title>Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate to severe active disease with presence of at least 4 tender joints and 4 swollen joints. Either the patient or a designee must be capable of administering the subcutaneous injection of study drug. Prior treatment with etanercept. Presence of active infection or active or untreated tuberculosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>